Track Deciphera Pharmaceuticals, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Deciphera Pharmaceuticals, Inc. DCPH · Stock Open Deciphera Pharmaceuticals, Inc. in new tab

25.59 USD
Loading chart...

DCF valuation

Model fair value for Deciphera Pharmaceuticals, Inc. (DCPH)
Result
Sign in to run the valuation for DCPH.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–

Deciphera Pharmaceuticals, Inc. Logo Deciphera Pharmaceuticals, Inc. Analysis (DCPH)

United States Health Care Official Website Stock

Is Deciphera Pharmaceuticals, Inc. a good investment? Deciphera Pharmaceuticals, Inc. (DCPH) is currently trading at 25.59 USD.

Investor FAQ

Does Deciphera Pharmaceuticals, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Deciphera Pharmaceuticals, Inc.?

Deciphera Pharmaceuticals, Inc. is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

Company Profile

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Exchange Ticker
FRA (Germany) D05.F
NMS (United States) DCPH
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion